1309774-03-5

Basic information

• Product Name: 7-BroMo-2-chloro-1,5-naphthyridine
• Synonyms: 7-BroMo-2-chloro-1,5-naphthyridine
• CAS NO: 1309774-03-5
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.48776
• Mol File: 1309774-03-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 319.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.762±0.06 g/cm3(Predicted)
• PKA: -0?+-.0.10(Predicted)
• CAS DataBase Reference: 7-BroMo-2-chloro-1,5-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BroMo-2-chloro-1,5-naphthyridine(1309774-03-5)
• EPA Substance Registry System: 7-BroMo-2-chloro-1,5-naphthyridine(1309774-03-5)

Safety Data

• Hazardous Substances Data: 1309774-03-5(Hazardous Substances Data)

Usage

General Description

7-bromo-2-chloro-1,5-naphthyridine is a chemical compound with the molecular formula C8H4BrClN2. It is a heterocyclic compound with a naphthyridine core structure, containing a bromine and a chlorine atom attached to the naphthyridine ring. 7-bromo-2-chloro-1,5-naphthyridine is frequently used as a building block in pharmaceutical and organic synthesis, and it has shown potential biological activity and therapeutic potential. It is also used as a reagent in various chemical reactions and as a precursor in the manufacture of other compounds. Additionally, 7-bromo-2-chloro-1,5-naphthyridine is stored and handled in accordance with standard chemical safety procedures due to its potential hazards.

Upstream product

• 27305-48-2 1,5-naphthyridine N-⁽¹⁾-oxide 
• 13535-01-8 3-amino-5-bromopyridine 
• 7689-62-5 2-chloro-1,5-naphthyridine 
• 10261-82-2 1,5-naphthyridin-2(1H)-one 
• 6298-19-7 2-chloro-3-aminopyridine 
• 39620-02-5 5-bromonicotinoyl chloride 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 28733-43-9 5-bromonicotinamide 
• 17965-71-8 3-bromo-1,5-naphthyridine 
• 959616-36-5 7-bromo-1,2-dihydro-1,5-naphthyridin-2-one 
• 56247-24-6 3-bromo-1,5-naphthyridine-5-oxide 
• 254-79-5 1,5-naphthyridine 
• 10261-82-2 2-Hydroxy-1,5-naphthyridin 

Downstream Products

• 1309773-60-1 1-tert-butyl-3-[7-(4-hydroxy-3-methoxyphenyl)-1,5-naphthyridin-2-yl]urea 
• 1422123-35-0 C₂₁H₂₂N₄O₃ 
• 1422123-99-6 C₂₂H₂₂N₆O 
• 1422124-32-0 C₂₁H₂₀N₆O 
• 1422124-72-8 C₂₁H₂₁N₅O₂ 
• 1422125-49-2 C₂₄H₂₅N₇O₄S 
• 1422125-93-6 C₂₂H₂₃N₇O 
• 1309774-09-1 1-benzyl-3-(7-bromo-1,5-naphthyridin-2-yl)urea 
• 1309774-08-0 1-(7-bromo-1,5-naphthyridin-2-yl)-3-phenylurea 
• 1422125-94-7 N-((7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl)carbamothioyl)benzamide 
• 1309773-66-7 1-ethyl-3-[7-(3,4,5-trimethoxy-phenylamino)-[1,5]naphthyridin-2-yl]-thiourea 
• 1309774-11-5 N₇-(3,4,5-trimethoxy-phenyl)-[1,5]naphthyridine-2,7-diamine 

Relevant articles and documents

SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.